ATL 101 - Alizyme

Drug Profile

ATL 101 - Alizyme

Alternative Names: ATL101 - Alizyme; AZM 128

Latest Information Update: 19 Oct 2001

Price : $50

At a glance

  • Originator Alizyme; Rowett Research Institute
  • Class Growth factors
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Mucositis

Most Recent Events

  • 19 Oct 2001 Discontinued-Preclinical for Mucositis in United Kingdom (Unknown route)
  • 03 Apr 2000 Alizyme has been granted exclusive rights to manufacturing technology for ALT 101
  • 30 Oct 1998 Alizyme is discussing out-licensing with potential partners
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top